Colonoscopy, endoscopy, fecal calprotectin, CRP, imaging, intestinal ultrasound, and monitoring research.
Page 4 of 33 · 1559 articles
Telenursing is increasingly used for chronic IBD care; understanding the limits and system factors that affect remote assessment matters because it influences how reliably nurses can detect and respond to flares and...
This study follows people from diagnosis and shows that about half achieve clinically meaningful improvements in quality of life by 3 years, but many remain below general population norms.
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Infliximab. The original article is from Inflammatory Bowel Diseases.
Noninvasive imaging that better separates inflammation from fibrosis and detects penetrating complications could change monitoring and treatment decisions in IBD and reduce radiation exposure for patients needing...
Patients on biologic therapy often have drug levels and antidrug antibodies measured to guide care. This study suggests prior biologic history, disease type (UC vs CD) and which biologic is currently used may affect...
The paper suggests serum bilirubin levels statistically explain a meaningful fraction of the link between gut Enterobacterales abundance and endoscopic disease activity in UC, which may point to biologic pathways or...
The study explores whether blood redox biomarkers relate to short- and long-term response to infliximab or vedolizumab, which could help predict who benefits from these biologics. It also suggests a link between...
Automated Lewis score estimation could make capsule endoscopy readings faster and more consistent, which may help track small-bowel Crohn disease activity. This study shows preliminary feasibility but not readiness for...
New Phase 3 data suggest subcutaneous risankizumab (Skyrizi) can achieve meaningful endoscopic remission and ulcer-free endoscopy rates in adults with active Crohn's disease, including higher responses in patients...
Endoscopic remission (visual healing) is linked to better long-term outcomes in Crohn's disease. An approved subcutaneous induction option could make risankizumab easier to use outside infusion settings.
Earlier identification of people likely to develop IBD could shorten diagnostic delays that are linked to worse outcomes, and an automated EHR model might help target who should get earlier evaluation.
The study suggests that using infliximab as first-line therapy (rather than IV corticosteroids) may produce more durable remission and reduce long-term colectomy risk in moderate-to-severe ulcerative colitis.
RDW-CV, a routine blood-test parameter, may help signal higher inflammatory activity in ulcerative colitis and provide low-cost adjunctive information when assessing disease activity.
This trial focuses on fibrostenosing Crohn’s disease, a form of IBD where strictures can block the intestine; a successful drug could offer a medical option to improve endoscopic passability and reduce need for...
Based on the title and source metadata, this appears to be a patient story related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from British medical journal.
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Tests and monitoring. The original article is from Inflammatory bowel diseases.
This advances a drug candidate (ontunisertib) aimed specifically at fibrostenosing Crohn’s disease — a form of IBD where strictures can block the bowel and endoscopic passability is a meaningful clinical measure.
Cure8 found this source from gastroendonews.com, but the page could not be read reliably yet. It is tagged for Tests and monitoring. Open the original article for the full details.
A new subcutaneous option for risankizumab (SKYRIZI) showed higher rates of endoscopic remission and ulcer-free endoscopy versus placebo in a Phase 3 Crohn's disease trial, which could expand at-home biologic options if...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Tests and monitoring. The original article is from British medical journal (Clinical research ed.).
Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. The original article is from British medical journal (Clinical...
Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. The original article is from British medical journal (Clinical...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Tests and monitoring. The original article is from British medical journal (Clinical research ed.).
Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease, Imaging, and Tests and monitoring. The original article is from Gut.
Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease and Tests and monitoring. The original article is from Gut.
Perianal fistulizing Crohn's disease causes major quality-of-life problems and is often hard to treat. This trial tests risankizumab in people who did not respond to or could not tolerate other standard therapies, and it...
Wearable-derived digital biomarkers could enable earlier, less burdensome detection of IBD flares and better remote monitoring if they reliably predict mucosal inflammation.
This OLE study follows patients who lost response to ustekinumab every-8-week dosing and evaluates whether increasing to every-4-week dosing maintains efficacy and safety long-term. That question is directly relevant to...
Researchers are investigating whether a specific gut bacterium (Pilosibacter rotomagensis) is linked to lower intestinal inflammation after surgery for ileal Crohn's disease. If true, this could point toward new...
This trial tests whether adding the oral antibiotic nifuroxazide to standard mesalamine improves quality of life for people with mild-to-moderate ulcerative colitis. Results, if published, could suggest a new adjunctive...
Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease and Tests and monitoring. The original article is from CMAJ : Canadian Medical Association journal =...
A fungal infection (paracoccidioidomycosis) can closely mimic Crohn’s disease on clinical, endoscopic, and histologic grounds, which risks misdiagnosis and harmful treatment delays—especially in patients from endemic...
The study suggests a decade-long preclinical phase of IBD detectable by blood metabolites, which could open opportunities for earlier identification of people at risk for Crohn’s disease and for studying early disease...
This trial suggests a structured whole-food diet may reduce subclinical intestinal inflammation (measured by fecal calprotectin) in asymptomatic children and young adults with Crohn's disease—offering a non-formula,...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from Patient Related Outcome...
Long-term Phase 3 extension data suggest guselkumab (Tremfya) may provide sustained clinical and endoscopic remission for some adults with moderate-to-severe Crohn's disease, which could expand treatment options for...
If true, the finding explains why symptoms can return after remission: the gut lining may remain biologically vulnerable even when inflammation seems controlled. That could point to new approaches aimed at 'molecular...
Cure8 could only read part of this source from Endoscopy, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring.
Long-term control of symptoms and intestinal inflammation is a major need in Crohn's disease. Three-year data showing sustained clinical and endoscopic remission and high rates of steroid-free remission could be...
Long-term (3-year) data on a biologic for Crohn's disease may indicate how durable treatment benefits and steroid-free remission can be for people considering or already on biologic therapy.
Perianal Crohn’s disease causes major symptoms and affects long-term outcomes; understanding surgical options and the role of combined medical–surgical care can help patients and clinicians plan treatment. The review...
A breath-based VOC test could offer a noninvasive, point-of-care way to help detect or screen for colon diseases including IBD. This study shows preliminary promise—especially for ulcerative colitis—but is early-stage...
A sizable minority of people newly diagnosed with IBD—about 1 in 5 with Crohn’s and 1 in 10 with ulcerative colitis—received no IBD-specific drugs within the first year. Understanding who is untreated and why could...
Early Phase 1 findings suggest a gut-targeted PDE4 prodrug may engage its target in diseased tissue and produce early improvements in symptoms, endoscopy, and tissue inflammation — findings that, if confirmed in Phase 2,...
The review links microbiome, metabolites, barrier function, and immune responses across anorectal disorders and ulcerative colitis — areas that directly affect symptoms, healing, and response to therapy.
Conference analyses describe how subcutaneous infliximab performs after stopping IV treatment and when compared with IV infliximab for ileal/ileocolonic Crohn's — information that could affect treatment decisions for...
This study describes how often people newly diagnosed with IBD go on biologic or JAK inhibitor therapy and what happened to them over five years — including hospital visits and surgery — which helps set expectations for...
The study suggests that about one-quarter of IBD patients treated with advanced therapies develop difficult-to-treat disease, and identifies timing of therapy, age, and specific therapy choice as predictors.
